Advanced

Adrenocorticotrophic hormone exerts marked lipid-lowering effects in simvastatin-treated patients

Hardarson, A; Sigurdsson, G; Olafsdottir, E and Berg, Anna-Lena LU (2001) In Journal of Internal Medicine1989-01-01+01:00 250(6). p.530-534
Abstract
Objective. Recently, it was reported that treatment with adrenocorticotrophic hormone (ACTH) has a strong lipid-lowering effect in healthy individuals. The mechanism behind this has not been established. The aim of the present investigation was to study the effect of ACTH on the plasma lipoprotein pattern in patients treated with a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor.



Design. The ACTH treatment was given to 10 patients who were on long-term treatment with simvastatin 40 mg daily. ACTH1-24 was administered at the dose of 1 mg daily for four consecutive days. Blood samples for analyses of lipids, lipoproteins and apolipoproteins were collected before and after treatment. Second baseline was obtained 2... (More)
Objective. Recently, it was reported that treatment with adrenocorticotrophic hormone (ACTH) has a strong lipid-lowering effect in healthy individuals. The mechanism behind this has not been established. The aim of the present investigation was to study the effect of ACTH on the plasma lipoprotein pattern in patients treated with a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor.



Design. The ACTH treatment was given to 10 patients who were on long-term treatment with simvastatin 40 mg daily. ACTH1-24 was administered at the dose of 1 mg daily for four consecutive days. Blood samples for analyses of lipids, lipoproteins and apolipoproteins were collected before and after treatment. Second baseline was obtained 2 weeks after the end of treatment.



Results. The serum concentrations of cholesterol, triglycerides, low density lipoprotein (LDL) cholesterol, apolipoprotein B and lipoprotein(a) fell significantly by 16, 23, 23, 10 and 38%, respectively. The serum apolipoprotein E concentration increased significantly by 39%; the fraction that was not associated with apolipoprotein B increased by 47% whereas the fraction that was did not change significantly. There were no changes in the serum concentrations of high density lipoprotein (HDL) cholesterol and apolipoprotein AI. At the second baseline, the lipid variables had generally returned to previous levels.



Conclusions. In patients on long-term simvastatin treatment, ACTH had marked lowering effects on the lipoproteins that contain apolipoprotein B. Moreover, the serum apolipoprotein E concentration increased significantly in response to ACTH treatment. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Internal Medicine1989-01-01+01:00
volume
250
issue
6
pages
530 - 534
publisher
Wiley-Blackwell Publishing Ltd
external identifiers
  • scopus:0035652615
ISSN
1365-2796
DOI
language
English
LU publication?
yes
id
c07ecdc5-bfe2-4896-ac8b-cf40092cbf54 (old id 1267099)
date added to LUP
2008-11-12 15:52:59
date last changed
2018-05-29 09:40:59
@article{c07ecdc5-bfe2-4896-ac8b-cf40092cbf54,
  abstract     = {Objective. Recently, it was reported that treatment with adrenocorticotrophic hormone (ACTH) has a strong lipid-lowering effect in healthy individuals. The mechanism behind this has not been established. The aim of the present investigation was to study the effect of ACTH on the plasma lipoprotein pattern in patients treated with a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor.<br/><br>
<br/><br>
Design. The ACTH treatment was given to 10 patients who were on long-term treatment with simvastatin 40 mg daily. ACTH1-24 was administered at the dose of 1 mg daily for four consecutive days. Blood samples for analyses of lipids, lipoproteins and apolipoproteins were collected before and after treatment. Second baseline was obtained 2 weeks after the end of treatment.<br/><br>
<br/><br>
Results. The serum concentrations of cholesterol, triglycerides, low density lipoprotein (LDL) cholesterol, apolipoprotein B and lipoprotein(a) fell significantly by 16, 23, 23, 10 and 38%, respectively. The serum apolipoprotein E concentration increased significantly by 39%; the fraction that was not associated with apolipoprotein B increased by 47% whereas the fraction that was did not change significantly. There were no changes in the serum concentrations of high density lipoprotein (HDL) cholesterol and apolipoprotein AI. At the second baseline, the lipid variables had generally returned to previous levels.<br/><br>
<br/><br>
Conclusions. In patients on long-term simvastatin treatment, ACTH had marked lowering effects on the lipoproteins that contain apolipoprotein B. Moreover, the serum apolipoprotein E concentration increased significantly in response to ACTH treatment.},
  author       = {Hardarson, A and Sigurdsson, G and Olafsdottir, E and Berg, Anna-Lena},
  issn         = {1365-2796},
  language     = {eng},
  number       = {6},
  pages        = {530--534},
  publisher    = {Wiley-Blackwell Publishing Ltd},
  series       = {Journal of Internal Medicine1989-01-01+01:00},
  title        = {Adrenocorticotrophic hormone exerts marked lipid-lowering effects in simvastatin-treated patients},
  url          = {http://dx.doi.org/},
  volume       = {250},
  year         = {2001},
}